Durchblutungsfördernde Mittel

  • Ulrich Schwabe


Der seit 1992 rückläufige Verordnungstrend durchblutungsfördernder Arzneimittel hat sich 2001 weiter fortgesetzt. Hauptursache ist vermutlich die ungenügende Beleglage, die eine Anwendung der zweifelhaft wirksamen Vasodilatatoren und die damit verbundenen hohen Kosten nicht mehr rechtfertigt.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Adhoute G., Andreassian B., Boccalon H., Cloarec M., Di Maria G. et al. (1990): Treatment of stage II chronic arterial disease of the lower limbs with the serotonergic antagonist naftidrofuryl: results after 6 months of a controlled, multicenter study. J. Cardiovasc. Pharmacol. 16 (Suppl. 3): S75–S80.PubMedGoogle Scholar
  2. Adhoute G., Bacourt E, Barral M., Cardon J.M., Chevalier J.M. et al. (1986): Naftidrofuryl in chronic arterial disease. Results of a six month controlled multicenter study using naftidrofuryl tablets 200 mg. Angiology 37: 160–167.PubMedCrossRefGoogle Scholar
  3. Arzneimittelkommission der Deutschen Apotheker (1995): Naftidrofuryl Infusionslösung. Pharmazeut. Ztg. 140: 2222.Google Scholar
  4. Barradell L. B., Brogden R.N. (1996): Oral naftidrofuryl. A review of its pharmacology and therapeutic use in the management of peripheral occlusive arterial disease. Drugs Aging 8: 299–322.PubMedCrossRefGoogle Scholar
  5. Bauer U. (1984): 6-Month double-blind randomised clinical trial of ginkgo biloba extract versus placebo in two parallel groups in patients suffering from peripheral arterial insufficiency. Arzneim. Forsch. 34: 716–720.Google Scholar
  6. Boccalon H., Lehert P., Mosnier M. (2001): Effect of naftidrofuryl on physiological walking distance in patients with intermittent claudication. Ann. Cardiol. Angiol. 50: 175–182.CrossRefGoogle Scholar
  7. Bollinger A., Frei Ch. (1977): Double-blind study of pentoxifylline against placebo in patients with intermittent claudication. Pharmatherapeutica 1: 557563.Google Scholar
  8. Clifford P.C., Davies P.W., Hayne J.A., Baird R.N. (1980): Intermittent claudication: is a supervised exercise class worth while? Brit. Med. J. 280: 1503–1505.CrossRefGoogle Scholar
  9. Clyne C.A.C., Galland R. B., Fox M.J., Gustave R., Jantet G.H., Jamieson C.W. (1980): A controlled trial of naftidrofuryl (Praxilene) in the treatment of intermittent claudication. Br. J. Surg. 67: 347–348.PubMedCrossRefGoogle Scholar
  10. Creasy T.S., McMillan P.J., Fletcher E.W.L., Collin J., Morris P.J. (1990): Is percutaneous transluminal angioplasty better than exercise for claudication? — Preliminary results from a prospective randomised trial. Eur. J. Vasc. Surg. 4: 135–140.PubMedCrossRefGoogle Scholar
  11. Cummings D.M., Ballas S.K., Ellison M.J. (1992): Lack of effect of pentoxifylline on red blood cell deformability. J. Clin. Pharmacol. 32: 1050–1053.PubMedCrossRefGoogle Scholar
  12. Dahllöf A.-G., Holm J., Scherstén T., Sivertsson R. (1976): Peripheral arterial insufficiency. Effect of physical training on walking tolerance, calf blood flow, and blood flow resistance. Scand. J. Rehab. Med. 8: 19–26.Google Scholar
  13. De Backer T.L., Vander Stichele R.H., Warie H.H., Bogaert M.G. (2000): Oral vasoactive medication in intermittent claudication: utile or futile ? Eur. J. Clin. Pharmacol. 56: 199–206.PubMedCrossRefGoogle Scholar
  14. Dettori A.G., Pini M., Moratti A., Paolicelli M., Basevi P. et al. (1989): Acenocoumarol and pentoxifylline in intermittent claudication. A controlled clinical study. Angiology 40: 237–248.PubMedCrossRefGoogle Scholar
  15. Di Perri T., Carandente O., Vittoria A., Guerrini M., Messsa G.L. (1984): Studies of the clinical pharmacology and therapeutic efficacy of pentoxifylline in peripheral obstructive arterial disease. Angiology 35: 427–435.PubMedCrossRefGoogle Scholar
  16. Donaldson D.R., Hall T.J., Kester R.C., Ramsden C.W., Wiggins P.A. (1984): Does oxpentifylline (`Trental’) have a place in the treatment of intermittent claudication ? Curr. Med. Res. Opin. 9: 35–40.PubMedCrossRefGoogle Scholar
  17. Dormandy J.A. (1996): Prostanoid drug therapy for arterial occlusive disease — the European experience. Vasc. Med. 1: 155–158.PubMedGoogle Scholar
  18. Drabzek H., Petersen J.R., Winberg N., Hansen K.F., Mehlsen J. (1996): The effect of Ginkgo biloba extract in patients with intermittent claudication. Ugeskr. Laeger 158: 3928–3931.Google Scholar
  19. Ekroth R., Dahllöf A.-G., Gundevall B., Holm J., Scherstén T. (1978): Physical training of patients with intermittent claudication: indications, methods, and results. Surgery 84: 640–643.PubMedGoogle Scholar
  20. Ernst E., Kollar L., Resch K.L. (1992): Does pentoxifylline prolong the walking distance in exercised claudicants? A placebo-controlled double-blind trial. Angiology 43: 121–125.PubMedCrossRefGoogle Scholar
  21. Ernst E. (1994): Pentoxifylline for intermittent claudication. A critical review. Angiology 45: 339–345.PubMedCrossRefGoogle Scholar
  22. Gallus A.S., Morley A.A., Dupont P., Walsh H., Gleadow R. et al. (1985): Intermittent claudication: a double-blind study crossover trial of pentoxifylline. Aust. N. Z. J. Med. 15: 402–409.PubMedCrossRefGoogle Scholar
  23. Girolami B., Bernardi E., Prins M.H., Wouter ten Cate J., Hettiarachchi R. et al. (1999): Treatment of intermittent claudication with physical training, smoking cessation, pentoxifylline, or nafronyl. Arch. Intern. Med. 159: 337–345.PubMedCrossRefGoogle Scholar
  24. Haberkamp T.J., Tanyeri H.M. (1999): Management of idiopathic sudden sensorineural hearing loss. Am. J. Otol. 20: 587–592.PubMedGoogle Scholar
  25. Heidrich H., Allenberg J., Cachovan M., Creutzig A., Diehm C. et al. (1992): Prüfrichtlinien für Therapiestudien im Fontaine-Stadium II-IV bei peripher-arterieller Verschlußkrankheit. Vasa 21: 333–337.PubMedGoogle Scholar
  26. Hiatt W.R., Regensteiner J.G., Hargarten M.E., Wolfel E.E., Brass E.P. (1990): Benefit of exercise conditioning for patients with peripheral arterial disease. Circulation 81: 602–609.PubMedCrossRefGoogle Scholar
  27. Hiatt W.R., Wolfel E.E., Meier R.H., Regensteiner J.G. (1994): Superiority of treadmill walking exercise versus strength training for patients with peripheral arterial disease. Circulation 90: 1866–1874.PubMedCrossRefGoogle Scholar
  28. Housley E. (1988): Treating claudication in five words. Brit. Med. J. 296: 1483–1484. Jonason T., Jonzon B., Ringqvist I., Oman-Rydberg A. (1979): Effect of physical training on different categories of patients with intermittent claudication. Acta Med. Scand. 206: 253–258.Google Scholar
  29. Karnik R., Valentin A., Stöllberger C., Slany J. (1988): Effects of naftidrofuryl in patients with intermittent claudication. Angiology 39: 234–240.PubMedCrossRefGoogle Scholar
  30. Kieffer E., Bahnini A., Mouren X., Gamand S. (2001): A new study demonstrates the efficacy of naftidrofuryl in the treatment of intermittent claudication. Findings of the Naftidrofuryl Clinical Ischemia Study (NCIS). Int. Angiol. 20: 58–65.PubMedGoogle Scholar
  31. Kiesewetter H., Blume J., Jung F., Gerhards M., Leipnitz G. (1987): Gehtraining und medikamentöse Therapie bei der peripheren arteriellen Verschlußkrankheit. Randomisierte, prospektive, placebo-kontrollierte Doppelblindstudie. Dtsch. Med. Wochenschr. 112: 873–878.PubMedCrossRefGoogle Scholar
  32. Kriessmann A., Neiss A. (1988): Klinischer Wirksamkeitsnachweis von Naftidrofuryl bei Claudicatio intermittens. VASA (Suppl. 24 ): 27–32.PubMedGoogle Scholar
  33. Larsen O.A., Lassen N.A. (1966): Effect of daily muscular exercise in patients with intermittent claudication. Lancet 2: 1093–1096.PubMedCrossRefGoogle Scholar
  34. Lindgärde F., Jelnes R., Björkman H., Adielsson G., Kjellström T. et al. (1989): Conservative drug treatment in patients with moderately severe chronic occlusive peripheral arterial disease. Circulation 80: 1549–1556.PubMedCrossRefGoogle Scholar
  35. Lundgren F., Dahllöf A.-G., Lundholm K., Scherstén T., Volkmann R. (1989): Intermittent claudication — surgical reconstruction or physical training ? Ann. Surg. 209: 346–355.PubMedCrossRefGoogle Scholar
  36. Mannarino E., Pasqualini L., Innocente S., Scricciolo V., Rignanese A., Ciuffetti G. (1991): Physical training and antiplatelet treatment in stage II peripheral arterial occlusive disease: alone or combined? Angiology 42: 513521.Google Scholar
  37. Moody A.P., Al-Khaffaf H.S., Lehert P., Harris P.L., Charlesworth D. (1994): An evaluation of patients with severe intermittent claudication and the effect of treatment with naftidrofuryl. J. Cardiovasc. Pharmacol. 23 (Suppl. 3): S44–S47.PubMedGoogle Scholar
  38. Norwegian Pentoxifylline Multicenter Trial Group (1996): Efficacy and clinical tolerance of parenteral pentoxifylline in the treatment of critical lower limb ischemia. Int. Angiol. 15: 75–80.Google Scholar
  39. Pedersen T.R., Kjekshus J., Pyörälä K., Olsson A.G., Cook T.J. et al. (1998): Effect of Simvastatin on ischemic signs and symptoms in the Scandinavian Simvastatin Survival Study (4S). Am. J. Cardiol. 81: 333–335.PubMedCrossRefGoogle Scholar
  40. Porter J.M., Cutler B.S., Lee B.Y., Reich Th., Reichle F.A. et al. (1982): Pentoxifylline efficacy in the treatment of intermittent claudication. Multicenter controlled double-blind trial with objective assessment of chronic occlusive arterial disease patients. Am. Heart J. 104: 66–72.PubMedCrossRefGoogle Scholar
  41. Probst R., Tschopp K., Ludin E., Kellerhals B., Podvinec M., Pfaltz C.R. (1992): A randomized, double-blind, placebo-controlled study of dextran/pentoxifylline medication in acute acoustic trauma and sudden hearing loss. Acta Otolaryngol. 112: 435–443.PubMedCrossRefGoogle Scholar
  42. Quick C.R., Cotton L.T. (1982): The measured effect of stopping smoking on intermittent claudication. Brit. J. Surg. 69 (Suppl.): S24–S26.PubMedCrossRefGoogle Scholar
  43. Radack K., Wyderski R.J. (1990): Conservative management of intermittent claudication. Ann. Intern. Med. 113: 135–146.PubMedCrossRefGoogle Scholar
  44. Reilly D.T., Quinton D.N., Barrie W.W. (1987): A controlled trial of pentoxifylline (Trental 400) in intermittent claudication: clinical, haemostatic and rheological effects. New Zeal. Med. J. 100: 445–447.Google Scholar
  45. Reisser C., Weidauer H, (2001): Ginkgo biloba extract Egb 761® or pentoxifylline for the treatment of sudden deafness: a randomized, reference-controlled, double-blind study. Acta Otolaryngol. 121: 579–584.PubMedCrossRefGoogle Scholar
  46. Rieger H., Hossmann V. (1998): Medikamentöse Durchblutungssteigerung bei chronischer peripherer arterieller Verschlußkrankheit. In: Rieger H., Schoop W. (Hrsg.): Lehrbuch der Angiologie. Springer Verlag Berlin Heidelberg New York, S. 239–252.Google Scholar
  47. Roekaerts F., Deleers L. (1984): Trental® 400 in the treatment of intermittent claudication: results of long-term, placebo-controlled administration. Angiology 35: 396–406.PubMedCrossRefGoogle Scholar
  48. Rudofsky G., Haussler K.F., Kunkel H.P., Schneider-May H., Spengel F., Symann O., Werner H.-J. (1989): Intravenous treatment of chronic peripheral occlusive arterial disease: a double-blind, placebo-controlled, randomized, multicenter trial of pentoxifylline. Angiology 40: 639–649.PubMedCrossRefGoogle Scholar
  49. Scheffler A., Rieger H. (1999): Arterielle Durchblutungsstörungen. In: Paumgartner G. (Hrsg.): Therapie innerer Krankheiten. 9. Aufl., Springer Verlag Berlin Heidelberg New York, S. 257–273.Google Scholar
  50. Scheffler P., de la Hamette D., Gross J., Mueller H., Schieffer H. (1994): Intensive vascular training in stage IIb of peripheral arterial occlusive disease. The additive effects of intravenous prostaglandin El or intravenous pentoxifylline during training. Circulation 90: 818–822.PubMedCrossRefGoogle Scholar
  51. Schoop W., Breddin K., Diehm C., Gruß J., Held K. et al. (1996): Klinische Prüfung mit Ginkgo biloba-Spezialextrakt Egb 761 bei Patienten mit peripherer arterieller Verschlußkrankheit im Stadium II b nach Fontaine im Vergleich zu Placebo. Posterpublikation, Jahreskongress der Schweizerischen Gesellschaft für Angiologie 1.-2. 11. 1996.Google Scholar
  52. Strano A., Davi G., Avellone G., Novo S., Pinto A. (1984): Double-blind, crossover study of the clinical efficacy and the hemorheological effects of pentoxifylline in patients with occlusive arterial disease of the lower limbs. Angiology 35: 459–466.PubMedCrossRefGoogle Scholar
  53. Transparenzkommission (1983): Transparenzliste für das Teilgebiet periphere arterielle Durchblutungsstörungen. Bundesanzeiger Nr. 169 vom 9. 9. 1983.Google Scholar
  54. Trübestein G., Böhme H., Heidrich H., Heinrich F., Hirche H., Maass U. et al. (1984): Naftidrofuryl in chronic arterial disease. Results of a controlled multicenter study. Angiology 35: 701–708.PubMedCrossRefGoogle Scholar
  55. Völker D. (1983): Treatment of arteriopathies with pentoxifylline (Trental 400): results of a double-blind study. Pharmatherapeutica 3 (suppl. 1): 136–142.Google Scholar
  56. Walker G.A., MacMannaford J.C. (1995): A meta-analysis of randomized, double-blind, placebo-controlled studies of the effect of buflomedil on intermittent claudication. Fundam. Clin. Pharmacol. 9: 387–394.PubMedCrossRefGoogle Scholar
  57. Weinaug P. (1984): Die Spontanremission beim Hörsturz. HNO 32: 346–351.PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2003

Authors and Affiliations

  • Ulrich Schwabe

There are no affiliations available

Personalised recommendations